Leftwich Scott bought CLDI
December 21, 2023 · Form 4 insider transaction
Leftwich Scott bought 70,249 shares of Calidi Biotherapeutics, Inc., a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 14 days after the transaction.
Footnotes
Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on December 21, 2023 (the "Grant Date"), the Reporting Person was granted 70,249 Non-Qualified Stock Options (the "Options") at an exercise price of $1.80, which is equal to the closing price of the Issuer's common stock on December 21, 2023, for serving as a director. Options will vest in one year or at the next annual shareholder meeting, whichever occurs first. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.